Esomeprazole
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2001
- First approval year
- 2001
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Esomeprazole
- Molecular weight
- 345.42
- Structure (SMILES)
- COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1
- a02bc05
- A02BC05
- esomeprazol
- Esomeprazol
- esomeprazol 40mg sodium bicarbonate 721mg
- esomeprazole
- Esomeprazole
- esomeprazole [INN]
- ESOMEPRAZOLE [MART.]
- ESOMEPRAZOLE [VANDF]
- Esomeprazole [WHO-DD]
- esomeprazole inn
- esomeprazole mart
- esomeprazole vandf
- esomeprazole who dd
- h199 18
- H199/18
- inexium paranova
- Inexium paranova
- omeprazole s
- omeprazole s form
- omeprazole s form mi
- Omeprazole s-form
- OMEPRAZOLE S-FORM [MI]
- Omeprazole, (s)-
And 2 more, listed on the interactive page.
- ATC classification codes
- A02BC05
Sources for recorded values
- CAS registry numbers
- 119141-88-7
- ChEMBL ID
- CHEMBL1201320
- InChIKey
- SUBDBMMJDZJVOS-DEOSSOPVSA-N
- PubChem compound IDs
- 9568614
- RxNorm IDs (RxCUI)
- 283742
- FDA ingredient codes (UNII)
- N3PA6559FT
- Applicant
- ASTRAZENECA
- Approval date
- 20 Feb 2001
- Application number
- NDA021153
- Status
- Authorised
- Status date
- 26 Aug 2013
- Authorisation date
- 26 Aug 2013
- Approved indications
- Nexium Control is indicated for the short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults.
- Product number
- EMEA/H/C/002618
- Authorisation holder
- Haleon Ireland Dungarvan Limited
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Gastroesophageal Reflux
European medicines record
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Over the counter
- United States (FDA)
- Approved
- European Union (EMA)
- Authorised
- Pharmacology name
- esomeprazole
- Type
- Synthetic organic
- Drug name stem
- -prazole
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- ATP4A
- Gene symbol
- ATP4A
- Protein identifier
- P20648
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- Potassium-transporting ATPase inhibitor
- Action type
- Inhibitor
- Target
- Potassium-transporting ATPase
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- ATP4A|ATP4B
- Protein identifier
- P20648|P51164
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Gastritis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000217
- Subject identifier
- D005756
- Condition
- Gastritis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000337
- Subject identifier
- D005756
- Condition
- Lymphoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Pre-Eclampsia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000668
- Subject identifier
- D011225
- Condition
- Hypertension, Pulmonary
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001361
- Subject identifier
- D006976
- Condition
- Arthritis, Juvenile
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002609
- Subject identifier
- D001171
- Condition
- Child Development Disorders, Pervasive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003756
- Subject identifier
- D002659
- Condition
- Autistic Disorder
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003758
- Subject identifier
- D001321
- Condition
- Breast Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003869
- Subject identifier
- D001943
- Condition
- Gastroesophageal Reflux
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003948
- Subject identifier
- D005764
- Condition
- Eosinophilic Esophagitis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004232
- Subject identifier
- D057765
- Condition
- Hepatitis B, Chronic
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004239
- Subject identifier
- D019694
- Condition
- Duodenal Ulcer
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004607
- Subject identifier
- D004381
- Condition
- Neuralgia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005762
- Subject identifier
- D009437
- Condition
- Dyspepsia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0008533
- Subject identifier
- D004415
- Condition
- Stomach Ulcer
- Highest recorded phase
- 3
- Condition identifier
- EFO:0009454
- Subject identifier
- D013276
- Condition
- Digestive System Diseases
- Highest recorded phase
- 3
- Condition identifier
- EFO:0010282
- Subject identifier
- D004066
- Condition
- Helicobacter Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000961
- Subject identifier
- D016481
- Condition
- Esophagitis, Peptic
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001095
- Subject identifier
- D004942
- Condition
- Non-alcoholic Fatty Liver Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001249
- Subject identifier
- D065626
- Condition
- Nausea
- Highest recorded phase
- 3
- Condition identifier
- HP:0002018
- Subject identifier
- D009325
- Condition
- Gastrointestinal Hemorrhage
- Highest recorded phase
- 3
- Condition identifier
- HP:0002239
- Subject identifier
- D006471
- Condition
- Peptic Ulcer
- Highest recorded phase
- 3
- Condition identifier
- HP:0004398
- Subject identifier
- D010437
- Condition
- Peptic Ulcer
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004247
- Subject identifier
- D010437
And 7 more, listed on the interactive page.
- Condition identifier
- EFO_0000217
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000280
- Condition identifier
- EFO_0000319
- Condition identifier
- EFO_0000337
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000668
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002609
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003756
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003758
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003948
- Condition identifier
- EFO_0004607
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005762
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005769
- Condition identifier
- EFO_0007533
- Condition identifier
- EFO_0008533
- Highest recorded phase
- 3
- Condition identifier
- EFO_0008572
- Condition identifier
- EFO_0009364
- Condition identifier
- EFO_0009454
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009673
- Highest recorded phase
- 3
- Condition identifier
- EFO_0010282
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000274
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000961
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001095
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001249
- Condition identifier
- EFO_1001355
- Condition identifier
- HP_0001609
And 44 more, listed on the interactive page.
- Event
- acute kidney injury
- Reports
- 2,932
- Reporting signal score
- 2,892.48
- Event
- agranulocytosis
- Reports
- 577
- Reporting signal score
- 620.222
- Event
- carotid artery thrombosis
- Reports
- 26
- Reporting signal score
- 88.5244
- Event
- cholestasis
- Reports
- 612
- Reporting signal score
- 669.3
- Event
- chronic kidney disease
- Reports
- 3,125
- Reporting signal score
- 8,833.18
- Event
- colitis microscopic
- Reports
- 351
- Reporting signal score
- 756.933
- Event
- confusional state
- Reports
- 168
- Reporting signal score
- 76.9689
- Event
- drug interaction
- Reports
- 1,797
- Reporting signal score
- 717.936
- Event
- drug reaction with eosinophilia and systemic symptoms
- Reports
- 743
- Reporting signal score
- 756.302
- Event
- end stage renal disease
- Reports
- 671
- Reporting signal score
- 1,749.72
- Event
- eosinophilia
- Reports
- 97
- Reporting signal score
- 142.804
- Event
- gastrooesophageal reflux disease
- Reports
- 138
- Reporting signal score
- 147.107
- Event
- hepatocellular injury
- Reports
- 657
- Reporting signal score
- 716.875
- Event
- hypocalcaemia
- Reports
- 1,333
- Reporting signal score
- 2,487.55
- Event
- hypokalaemia
- Reports
- 1,081
- Reporting signal score
- 1,058.39
- Event
- hypomagnesaemia
- Reports
- 2,031
- Reporting signal score
- 5,319.51
- Event
- hyponatraemia
- Reports
- 2,714
- Reporting signal score
- 4,074.5
- Event
- interstitial lung disease
- Reports
- 114
- Reporting signal score
- 100.395
- Event
- neurologic neglect syndrome
- Reports
- 26
- Reporting signal score
- 101.556
- Event
- personality disorder
- Reports
- 42
- Reporting signal score
- 123.339
- Event
- polycystic ovaries
- Reports
- 25
- Reporting signal score
- 78.0649
- Event
- prescription form tampering
- Reports
- 27
- Reporting signal score
- 79.9866
- Event
- rash maculo-papular
- Reports
- 88
- Reporting signal score
- 98.1314
- Event
- rebound acid hypersecretion
- Reports
- 26
- Reporting signal score
- 107.895
- Event
- renal failure
- Reports
- 1,115
- Reporting signal score
- 649.158
And 5 more, listed on the interactive page.
- NCT00123656
- NCT00164788
- NCT00251979
- NCT00402259
- NCT00164840
- NCT00241501
- NCT00241514
- NCT00241540
- NCT00251927
- NCT00251966
- NCT00427635
- NCT00468559
- NCT00626535
- NCT00658528
- NCT00658632
- NCT00658775
- NCT00684190
- NCT00730665
- NCT00857597
- NCT01059383
- NCT01089959
- NCT01107938
- NCT01750437
- NCT02028663
- NCT02456935
And 62 more, listed on the interactive page.
- Dose
- 20 mg or 40 mg
- Route
- Oral
- How often
- Once daily
Conditions of use
- Take at least one hour before meals
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 1
- Polar surface area
- 83.09
- Calculated partition coefficient (ALogP)
- 2.9
- Calculated partition coefficient (XLogP)
- 2.2
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 24
- Molecular formula
- C17H19N3O3S
- Monoisotopic mass
- 345.11471265
- Natural product
- Yes
- 33342-306
- 33342-307
- Recorded assays
- 58
- Active assays
- 3
- Confirmatory
- Other
- Anti-Ulcer Agents
- Proton Pump Inhibitors
Oral bioavailability
- Median
- 90
- Mean
- 90
- Minimum
- 90
- Maximum
- 90
- Unit
- %
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Plasma protein binding
- Median
- 98
- Mean
- 98
- Minimum
- 96
- Maximum
- 100
- Unit
- %
- Assays
- 3
- Standard deviation
- 2
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- PPB
Related records
Trials (352)
- 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection
- 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)
- 15-day Sequential Therapy for Helicobacter Pylori Infection in Korea
- A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued
- A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued in Subjects in the US Only
- A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain
- A Comparison of Gastric pH Control With High Dose Intravenous or Oral Esomeprazole
- A Double Blind Study Comparing Two Doses of IV Esomeprazole After Successful Endoscopic Therapy
- A Healthy Female and Male Volunteers Aspirin Study
- A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding
- A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis
- A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)
- A Multiple Dose Study of LY3502970 in Healthy Participants
- A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels
- A Phase 1 Study of Tegoprazan on Healthy Male Volunteers
- A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia
- A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection
- A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients
- A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks
Approved for (1)
In development for (37)
- Asthma Phase 2
- Autism Phase 2
- Autism spectrum disorder Phase 2
- Barrett esophagus Phase 1
- Breast cancer Phase 2
- Breast neoplasm Phase 1
- Chronic gastritis Phase 3
- Chronic hepatitis B virus infection Phase 1
- Cystic fibrosis Phase 2
- Duodenal ulcer Phase 3
- Dyspepsia Phase 2
- Eosinophilic esophagitis Phase 2
- Esophageal cancer Phase 3
- Esophageal ulcer Phase 2
- Esophagitis Phase 3
- Fatty liver disease Phase 1
- Gastric mucosa-associated lymphoid tissue lymphoma Phase 2
- Gastric ulcer Phase 3
- Gastritis Phase 3
- Gastroesophageal reflux disease Phase 3
Other linked conditions (8)
- Adenocarcinoma
- Calcium metabolic disease
- Gastric cancer
- Gastroparesis
- Myocardial infarction
- Parkinson disease
- Pharyngitis
- Vasomotor rhinitis